Expert-driven innovation
Our dedicated CAP-affiliated laboratory directors are board-certified physicians and clinical laboratory scientists who engage in clinical practice as well as research. Bringing clinical experience to the test development arena enables evidence-based innovation rooted in patient outcomes. A partnership with BioPharma Diagnostics provides access to a vast testing library as well as a wealth of patient-centric expertise to optimize clinical trial and drug development.
“Laboratory medicine creates amazing value for any healthcare organization because it's creating data and that data is very valuable. It can drive practice, it can drive cost, it can drive cost deflection, and it can drive insights.”
The latest
Mayo Clinic Laboratories is excited to participate in the 65th ASH Annual Meeting & Exposition, which will take place in San Diego on Dec. 9–12, 2023.
The nonprofit patient advocacy group called The MOG Project supports patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which is a rare and debilitating central nervous system demyelinating disorder. A team of Mayo Clinic neurologists, neuro-ophthalmologists, and the Autoimmune Neurology Laboratory at Mayo Clinic share a unique relationship with The MOG Project as they harness the power of patients’ experiences with MOGAD and their biospecimen data to advance the science behind this disease.
Mayo Clinic launched an automated system called RENEW — reanalysis of negative whole-exome/genome data — in 2022 that tracks newly published discoveries of disease-causing genetic variants. Every three months, the system automatically uploads these new scientific findings from around the world, which are then compared to the Mayo Clinic Center for Individualized Medicine’s database of unsolved patient sequencing results. This comparison helps to identify potentially significant developments that could lead to a new diagnosis for a patient with a rare genetic disorder.
Mayo Clinic Laboratories’ MayoComplete Melanoma Panel is a comprehensive test that better informs the prognosis and treatment of melanoma. It can be applied to unusual tumors that haven’t yet been identified as melanoma as well as melanomas with complex molecular structures.
Mayo Clinic Laboratories has developed a new colorectal cancer test, the MayoComplete Colorectal Cancer Panel (Mayo ID: MCCRC), in response to the latest recommendations for testing and treatment from the American Society of Clinical Oncology.
The MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor evaluates for somatic mutations in solid tumor samples and determines microsatellite instability to confirm a diagnosis of GIST.
Mayo Clinic Laboratories’ new MayoComplete Lung Cancer Panel (Mayo ID: MCLNG) provides more information than single-gene assays and faster results than a comprehensive solid tumor panel that covers hundreds of genes.
Mayo Clinic researchers and collaborators have discovered a critical role that inflammation plays in liver regeneration after liver resection. While effective regeneration requires some inflammation, too much of it causes regeneration failure. They also discovered that patients experiencing dysfunctional liver regeneration had a significantly dysregulated gene known as DUSP4 – a finding that could help support targeted therapeutic strategies administered before or after surgical resection to prevent liver failure.
Mayo Clinic researchers are now using artificial intelligence (AI) systems to help increase polyp detection during colonoscopies and identify colorectal cancer at an early stage. Like facial recognition software that recognizes faces, this AI tool is being trained to recognize polyps. It works alongside the physician during a colonoscopy, scanning the video feed and drawing boxes around polyps that may otherwise have been overlooked due to their subtleness.
The MayoComplete Liquid Biopsy Panel offers a noninvasive alternative to traditional cell-based biopsies. This allow for faster turnaround time and the ability to perform molecular DNA testing in cancer patients where tumor tissue isn’t available.